Zenas BioPharma (ZBIO) has just cleared a major clinical hurdle, reporting that lead antibody obexelimab met primary and key secondary endpoints in a Phase 3 IgG4-related disease trial while also starting first-in-human dosing for oral IL-17 inhibitor ZB021.

Despite the positive obexelimab Phase 3 result and progress with ZB021, momentum in the share price has cooled recently, with the stock down 30.53% on a 90 day share price return and 46.84% year to date, even as the 1 year total shareholder return stands at 75.17%.

If this kind of pipeline news has your attention, it can be useful to see what else is moving in related areas and compare how other healthcare AI driven opportunities are priced using the 32 healthcare AI stocks.

With the stock down sharply this year despite positive obexelimab data and a growing immunology pipeline, the key question for you is whether current prices still underestimate Zenas BioPharma or whether the market already reflects its potential for future growth.

Preferred Price-to-Book of 3.4x: Is It Justified?

On a P/B of 3.4x at a last close of $18.34, Zenas BioPharma looks cheaper than its closest peers on one comparison, yet more expensive on another.

The P/B ratio compares the company’s market value to the book value of its net assets. This can be a common reference point for clinical stage biopharma stocks that are still loss making and generating limited revenue.

For Zenas BioPharma, the P/B of 3.4x is described as good value against similar companies, where the peer average sits at 4.7x. This suggests the stock is pricing its asset base at a lower multiple than many close comparables. At the same time, it is described as expensive relative to the broader US Biotechs industry, where the average P/B is 2.4x, indicating the wider group trades at a lower multiple of book value than Zenas BioPharma.

Result: Price-to-book of 3.4x (ABOUT RIGHT)

However, there are clear risks here, including trial or regulatory setbacks for obexelimab and ongoing losses, with net income at a reported loss of $425.151 million.

Next Steps

With mixed signals across valuation, recent returns and clinical progress, the picture is not straightforward. It therefore makes sense to check the data yourself and decide quickly where you stand using the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one stock. Use these focused sets of ideas to spot opportunities others might overlook.

• Target quality at a discount by scanning for companies that combine strong fundamentals with appealing valuations through the 50 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that offer higher yields and resilient payouts via the 12 dividend fortresses.
• Prioritize resilience by checking companies with sturdier finances using the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.